Receiving a milestone fee in connection with the Phase 1 clinical trial initiation under the collaboration with Novartis. Revenue recognition is planned for the third quarter of the fiscal year ending December 2026 (amount not disclosed). No impact on earnings guidance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4587","jir_company_name":"PeptiDream Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4587-20260812-01.pdf","jir_short_summary":"Receiving a milestone fee in connection with the Phase 1 clinical trial initiation under the collaboration with Novartis. Revenue recognition is planned for the third quarter of the fiscal year ending December 2026 (amount not disclosed). No impact on earnings guidance.","jir_summary":"### Impact on performance and milestone revenue\nWe announced the receipt of a milestone fee associated with the Phase 1 clinical trial initiation under the joint research and development agreement with Novartis. Revenue is scheduled to be recognized in the third quarter of the fiscal year ending December 2026, with the amount not disclosed. The progress to this clinical stage underscores the strength of the collaboration and research capabilities. There is no change to existing earnings guidance.\n\n### Outlook and disclosure policy\nThis matter is expected to result in milestone revenue inflows aligned with clinical trial progress and has already been incorporated into the FY2026 earnings guidance. Since the amount is not disclosed at this time, additional information will be disclosed to investors in a timely manner when available.","jir_financial_highlights":"Milestone fee receipt: Unknown (Unknown)\nRecognition of revenue for Q3 of FY2026: Unknown (Unknown)","jir_category":"","jir_hashtags":"#PeptiDream, #ClinicalTrial, #MilestoneFee, #Radiopharmaceutical, #PDPS","jir_key_figures":"Milestone fee receipt: amount unknown\nRecognition of revenue for Q3 FY2026: amount unknown\nIn earnings guidance disclosed on Feb 16, 2026, already incorporated, no change","jir_meta_title":"PeptiDream: Milestone Receipt from Phase 1 Trial Start with Novartis | FY2026 Dec Year","jir_meta_description":"PeptiDream receives milestone payment from Novartis for the Phase 1 clinical trial start. Revenue recognition planned for Q3 FY2026; amount undisclosed. No impact on earnings guidance.","jir_og_title":"PeptiDream Receives Milestone for Trial Start with Novartis","jir_og_description":"Milestone received due to the start of Phase 1 clinical trial in collaboration with Novartis. Revenue recognition planned for Q3 FY2026; amount undisclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8926,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-101723","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n